While Northwestern swims like Scrooge McDuck [1] in its $700 million Lyrica payment, Sloan-Kettering Institute for cancer research is suing Amgen for underpaying royalties by more than $72 million. The cancer center claims that, when calculating royalties, Amgen deducted Aranesp [2]-related rebates from Neupogen and Neulasta sales. The latter two drugs sold at a rate of $1.1 billion just in the third quarter. Amgen denies the claims.
- check out this report [3]
- read the Pharmalot item [4]
Related Articles:
Northwestern sells Lyrica rights for $700M. Report [5]
Lyrica OK'd for epilepsy. Report [6]
Links:
[1] http://www.fiercepharma.com/story/northwestern-sells-lyrica-rights-for-700m/2007-12-19?utm_medium=nl&utm_source=link
[2] http://www.fiercepharma.com/special-reports/2-epogen-aranesp-top-10-warnings-and-recalls
[3] http://money.cnn.com/news/newsfeeds/articles/djf500/200712191752DOWJONESDJONLINE000978_FORTUNE5.htm
[4] http://www.pharmalot.com/2007/12/big-pharma-big-institutions-big-royalties/
[5] http://www.fiercepharma.com/story/northwestern-sells-lyrica-rights-for-700m/2007-12-19?utm_medium=nl&utm_source=link
[6] http://www.fiercebiotech.com/story/spotlight-lyrica-ok-d-for-epilepsy/2005-06-13
